Phospho-CDK1 (T161) Antibody

What is the biological significance of CDK1 T161 phosphorylation?

Phosphorylation of CDK1 at threonine 161 is essential for the activation of this kinase and the onset of mitosis. This posttranslational modification occurs in the activation loop of CDK1 and is required for proper cell cycle progression, particularly at the G2/M transition. The phosphorylation at T161 increases the catalytic activity of CDK1 when complexed with cyclins, enabling the phosphorylation of downstream substrates that drive mitotic events . CDK1 is a critical kinase with a calculated molecular weight of 34kDa that controls cell division and plays a vital role in regulating the transition from G2 to M phase of the cell cycle .

How does T161 phosphorylation interact with other CDK1 phosphorylation events?

CDK1 activity is regulated by a complex interplay of phosphorylation events. Two-dimensional gel electrophoresis studies have revealed that the activating T161 phosphorylation is tightly coupled to the inhibitory T14 phosphorylation in cyclin B1-CDK1 complexes . Interestingly, this strict association could not be uncoupled by substantial reduction of T14 phosphorylation following Myt1 knockdown, suggesting a mechanistic relationship . This coupling may serve as a protective mechanism preventing premature activation of CDK1 by the constitutively active CDK-activating kinase (CAK) . Additionally, while T161 phosphorylation occurs alongside T14 phosphorylation, its relationship with Y15 phosphorylation appears less strict .

What is the subcellular localization pattern of phosphorylated CDK1 (T161)?

Phosphorylated CDK1 (T161) exhibits a complex subcellular distribution pattern that changes through the cell cycle. According to immunostaining data, phospho-CDK1 (T161) can be detected in multiple cellular compartments including the cytoplasm, mitochondrion, nucleus, centrosome, cytoskeleton, microtubule organizing center, and spindle . The distribution is particularly important for understanding the spatial regulation of CDK1 activity, as the different phosphorylation events involve kinases localized to distinct compartments: CAK (nuclear), Wee1 (nuclear), and Myt1 (associated with endoplasmic reticulum and Golgi membranes) . Immunohistochemical analysis has demonstrated both nuclear and cytoplasmic staining of phospho-CDK1 (T161) in cancer cells from human cervix cancer tissue .

What are the validated applications for Phospho-CDK1 (T161) antibodies?

Phospho-CDK1 (T161) antibodies have been validated for multiple experimental applications:

The antibody has been tested with human, mouse, and rat samples, with confirmed reactivity across these species .

How should samples be prepared for optimal phospho-CDK1 (T161) detection?

For optimal detection of phospho-CDK1 (T161), sample preparation should preserve phosphorylation status. Cell or tissue lysates should be prepared using phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in the lysis buffer. For Western blotting, a recommended blocking/dilution buffer is 5% non-fat dry milk (NFDM) in TBST . For immunohistochemistry applications, heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 is recommended prior to staining protocols . When comparing phosphorylation states between samples, standardized protein quantification and equal loading are essential. For two-dimensional gel electrophoresis, special care must be taken to preserve phosphorylation states during sample preparation to avoid artifacts, as noted in studies examining the relationship between different CDK1 phosphorylation forms .

What controls should be included when using phospho-CDK1 (T161) antibodies?

To ensure reliable results when using phospho-CDK1 (T161) antibodies, several controls should be employed:

• Positive control: HeLa cell lysate has been validated as a positive control for phospho-CDK1 (T161) detection .

• Phosphorylation specificity controls:

  • Phosphopeptide competition: Using the specific CDK1 phospho-T161 peptide versus non-phospho peptide in dot blot analysis can confirm antibody specificity .

  • Lambda phosphatase treatment: Treating a portion of your sample with lambda phosphatase should abolish the phospho-specific signal.

• Cellular treatment controls:

  • UV treatment: HeLa cells treated with UV for 90 minutes can alter phosphorylation patterns and serve as a biological control .

  • Cell cycle synchronization: Comparing samples from different cell cycle phases (especially G2/M transition) provides physiological context .

• Antibody controls:

  • Secondary antibody only control: Omit primary antibody to detect potential non-specific binding of secondary antibody .

  • Isotype control: Use same concentration of non-specific IgG from the same host species.

How can phospho-CDK1 (T161) antibodies be used to study cell cycle regulation mechanisms?

Phospho-CDK1 (T161) antibodies can be employed in sophisticated experimental designs to interrogate cell cycle regulation:

• Two-dimensional gel electrophoresis coupled with immunoblotting: This approach can resolve the seven phosphorylation combinations of CDK1 (1P15, 1P14, 1P161, 2P14,15, 2P14,161, 2P15,161, and 3P14,15,161), allowing researchers to track the dynamic changes in phosphorylation status throughout the cell cycle . This technique revealed that T161 phosphorylation is tightly coupled to T14 phosphorylation in cyclin B1-CDK1 complexes.

• Co-immunoprecipitation studies: By immunoprecipitating with cyclin-specific antibodies (cyclin B1 or cyclin A2) followed by phospho-CDK1 detection, researchers can analyze the phosphorylation status of specific CDK1-cyclin complexes . This approach revealed that phosphorylation at T161 is restricted to cyclin-bound CDK1, whereas Y15 and T14 phosphorylations can occur on monomeric CDK1 .

• Subcellular fractionation: Combining fractionation techniques with phospho-specific detection allows determination of compartment-specific phosphorylation patterns. Studies have shown different phosphorylation profiles between nuclear/Golgi fractions versus cytoplasmic fractions .

• Kinase inhibitor treatments: Using specific inhibitors like CGP (2 μM) in combination with stress treatments (e.g., UVC irradiation) can reveal the functional consequences of CDK1 phosphorylation on downstream processes .

What is the relationship between CDK1 T161 phosphorylation and cancer progression?

The relationship between CDK1 T161 phosphorylation and cancer progression represents an important research area. Immunohistochemical analysis of paraffin-embedded human cervix cancer tissue has shown pronounced nuclear and cytoplasmic staining of phospho-CDK1 (T161) , suggesting altered regulation in cancer cells. The tight coupling between T161 and T14 phosphorylations provides a mechanism that prevents premature mitotic entry, which when disrupted could contribute to genomic instability and cancer progression .

Research approaches to study this relationship include:

• Comparative analysis: Examining phospho-CDK1 (T161) levels in matched normal versus tumor tissues using immunohistochemistry or Western blotting.

• Correlation with clinical outcomes: Determining whether phospho-CDK1 (T161) levels correlate with tumor grade, stage, or patient survival.

• Combined analysis with cell cycle markers: Co-staining for phospho-CDK1 (T161) alongside other cell cycle regulators (cyclins, CDK inhibitors) to assess pathway dysregulation.

• Kinase manipulation studies: Modulating CDK1 activity through Myt1 or Wee1 knockdown has shown opposite effects, with Wee1 reduction inducing catastrophic mitoses , suggesting potential therapeutic approaches.

What are common technical challenges when detecting phospho-CDK1 (T161) and how can they be addressed?

Several technical challenges can arise when detecting phospho-CDK1 (T161):

• Low signal intensity: This is often due to low abundance of the phosphorylated form.

  • Solution: Enrich for mitotic cells where T161 phosphorylation is most abundant .

  • Increase protein loading (up to 40-60 μg total protein).

  • Consider using signal enhancement systems.

• Loss of phosphorylation during sample preparation:

  • Solution: Use fresh samples and maintain cold conditions during preparation.

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers.

  • Avoid multiple freeze-thaw cycles of samples.

• Cross-reactivity with other phosphorylated CDKs:

  • Solution: Some antibodies may cross-react with phosphorylated CDK2/CDK3 at T160, which is homologous to CDK1 T161 .

  • Validate specificity using phospho-peptide competition assays.

  • Consider using recombinant monoclonal antibodies for higher specificity .

• Background issues in immunohistochemistry:

  • Solution: Optimize antigen retrieval methods (heat-mediated with Tris/EDTA buffer pH 9.0 is recommended) .

  • Increase blocking time or concentration.

  • Include secondary antibody-only controls to identify non-specific binding .

How can I verify the specificity of phospho-CDK1 (T161) antibody in my experimental system?

Verifying antibody specificity is crucial for reliable results. Several approaches are recommended:

• Peptide competition assay: Pre-incubate the antibody with increasing concentrations of phospho-T161 peptide versus non-phospho peptide before application to Western blot or immunostaining. Specific signal should be competitively reduced by the phospho-peptide but not by the non-phospho peptide .

• Lambda phosphatase treatment: Treat duplicate samples with lambda phosphatase to remove phosphate groups. The phospho-CDK1 (T161) signal should disappear in treated samples.

• Genetic validation: Use siRNA knockdown of CDK1 to confirm signal specificity. The phospho-specific signal should decrease proportionally to total CDK1 reduction .

• Cell cycle synchronization: Synchronize cells at different cell cycle stages. The phospho-CDK1 (T161) signal should increase as cells progress toward mitosis and decrease in G1 phase .

• Validation across multiple techniques: Confirm findings using multiple detection methods (Western blot, immunofluorescence, flow cytometry) to ensure consistent results.

How should phospho-CDK1 (T161) data be analyzed in relation to other CDK1 phosphorylation sites?

When analyzing phospho-CDK1 (T161) data alongside other phosphorylation sites, several analytical approaches should be considered:

• Ratio analysis: Calculate the ratio of phospho-T161 to total CDK1 to normalize for expression differences. Similarly, determine ratios between different phosphorylation sites (T161/Y15, T161/T14) to assess relative phosphorylation levels.

• Phosphorylation profile analysis: Two-dimensional gel electrophoresis can resolve all seven phosphorylation combinations of CDK1. This approach has revealed that the activating T161 phosphorylation is predominantly associated with inhibitory phosphorylations (T14 and Y15) before mitosis, particularly in cyclin B1-CDK1 complexes .

• Temporal analysis: Track changes in phosphorylation patterns through the cell cycle. The active 1P161 form (phosphorylated only at T161) is minimal in G2 phase but becomes the predominant form during mitosis as inhibitory phosphorylations are removed .

• Cyclin association analysis: Distinguish between phosphorylation patterns in different cyclin-CDK1 complexes. Research has shown that cyclin A2-bound and cyclin B1-bound CDK1 have distinct phosphorylation profiles, with 2P15,161 detected only in cyclin A2-bound CDK1 .

• Subcellular distribution: Compare phosphorylation patterns between different cellular compartments. T161 phosphorylation is more prominent in nuclear/Golgi fractions, while cytoplasmic CDK1 consists mainly of unphosphorylated and monophosphorylated forms .

What are the implications of the tight coupling between T161 and T14 phosphorylations in cyclin B1-CDK1?

The tight coupling between T161 and T14 phosphorylations in cyclin B1-CDK1 has several significant implications for cell cycle regulation:

• Protective mechanism: This coupling suggests an intrinsic mechanism that protects the mitotic timer from premature activation by constitutively active CDK-activating kinase (CAK) . The activating T161 phosphorylation is effectively "locked" behind the inhibitory T14 phosphorylation.

• Traffic-dependent regulation: The coupling mechanism depends on unperturbed cyclin B1-CDK1 trafficking between cellular compartments. When leptomycin B was used to prevent cyclin B1-CDK1 complexes from accumulating in the cytoplasm, Myt1 knockdown could uncouple these phosphorylations .

• Differential effects of kinase inhibition: The coupling explains the opposite effects observed when reducing expression of Myt1 (T14 kinase) versus Wee1 (Y15 kinase). Only Wee1 reduction induces catastrophic mitoses, as T161 phosphorylation remains coupled to T14 even when Myt1 is knocked down .

• Sequential activation model: The data supports a model where CDK1 activation in mitosis does not result from direct T161 phosphorylation of unphosphorylated CDK1, but rather from dephosphorylation of inhibitory residues from already T161-phosphorylated complexes .

This coupling mechanism provides an important layer of regulation ensuring proper timing of mitotic entry and preventing premature activation of CDK1 during the cell cycle.

How does phospho-CDK1 (T161) analysis compare between different experimental models?

Analysis of phospho-CDK1 (T161) across different experimental models reveals important considerations for research design and data interpretation:

• Cell line variations: Different cell lines may exhibit varied baseline levels of phospho-CDK1 (T161). Studies have utilized HeLa cells as positive controls , while T98G cells have also been validated for phospho-CDK1 (T161) research . When transitioning between cell models, pilot studies should be conducted to establish baseline phosphorylation patterns.

• Species considerations: While the antibody shows reactivity with human, mouse, and rat samples , species-specific differences in phosphorylation regulation may exist. Immunohistochemical analysis of rat testis tissue has shown nuclear and cytoplasmic staining patterns for phospho-CDK1 (T161) , which should be considered when comparing across species.

• Normal versus cancer tissues: Phosphorylation patterns may differ significantly between normal and cancer tissues. Human cervix cancer tissue exhibits strong nuclear and cytoplasmic staining , potentially reflecting dysregulated cell cycle control.

• In vitro versus in vivo models: Cell culture models may not fully recapitulate the complex regulation observed in tissue samples. Tissue-specific microenvironments can influence CDK1 phosphorylation patterns, necessitating validation across model systems.

• Quantitative considerations: Semi-quantitative methods like Western blotting should be complemented with more quantitative approaches like ELISA when making precise comparisons between models . The RayBio® Human Phospho-CDK1 (Thr161) and Total CDK1 ELISA Kit offers a semi-quantitative measurement of both phosphorylated and total CDK1 in cell lysate samples .

When designing comparative studies, these factors should be accounted for to ensure meaningful interpretation of phospho-CDK1 (T161) data across experimental models.